Resolution No. 6/19-4

ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES
VACCINES FOR CHILDREN PROGRAM VACCINES TO PREVENT POLIOMYELITIS

The purpose of this resolution is to update the Recommended Vaccination Schedule and Intervals section to reflect the currently available inactivated polio vaccine (IPV) and IPV-containing vaccines that can be used to prevent polio.

VFC resolution 06/09-1 is repealed and replaced by the following:

Eligible groups
All infants and children at least six weeks of age.

Recommended Schedule and Intervals for Polio-containing Vaccines
The table below indicates single antigen and combination vaccines licensed and currently available for routine use to prevent polio.

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Brand(s)</th>
<th>Schedule</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>IPV</td>
<td>Ipol</td>
<td>2,4,6-12 mos; 4-6 yrs</td>
<td>Approved for use in infants and adults</td>
</tr>
<tr>
<td>DTaP-HepB-IPV</td>
<td>Pediarix</td>
<td>2,4,6 mos</td>
<td>Approved for first 3 doses of IPV through 6 yrs</td>
</tr>
<tr>
<td>DTaP-IPV/Hib</td>
<td>Pentacel</td>
<td>2,4,6 and 12 mos</td>
<td>Approved for 4 doses of IPV through 4 yrs</td>
</tr>
<tr>
<td>DTaP-IPV-Hib-HepB</td>
<td>Vaxelis</td>
<td>2,4,6 mos</td>
<td>Approved for first 3 doses of IPV through 4 yrs</td>
</tr>
<tr>
<td>DTaP-IPV</td>
<td>Kinrix,</td>
<td>4-6 yrs</td>
<td>Approved for booster dose at age 4-6 yrs</td>
</tr>
<tr>
<td></td>
<td>Quadracel</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Additional details can be found at:
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5830a3.htm?s_cid=mm5830a3_e*

Recommended dosage
Refer to product package inserts.

Contraindications and Precautions
Contraindications and Precautions can be found in the package inserts available at:
https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states

[If an ACIP recommendation or notice regarding polio vaccination is published within 6 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]
Adopted and Effective: June 26, 2019

This document can be found on the CDC website at:
https://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html